Skip to content

Semaglutide studies: 1,194 papers with results

Page 23 of 24

  1. Glucagon-like peptide receptor agonists and risk for depression.

    Tagliapietra GA · Primary care diabetes · 2024

    Not a test of Semaglutide alone · 6 results

  2. Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome.

    De Sio V · International journal of cardiology · 2025

    Not a test of Semaglutide alone · 3 results

  3. The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review.

    Asiabar AS · European journal of clinical pharmacology · 2024

    Not a test of Semaglutide alone · 3 results

  4. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

    Dutta D · Indian journal of endocrinology and metabolism · 2024

    Not a test of Semaglutide alone · 12 results

  5. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.

    Tinsley GM · SAGE open medical case reports · 2025

    Not a test of Semaglutide alone · 6 results

  6. CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.

    Jacobsen JM · Nature metabolism · 2025

    Not a test of Semaglutide alone · 7 results

  7. Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.

    Sinha B · Obesity (Silver Spring, Md.) · 2025

    Not a test of Semaglutide alone · 12 results

  8. Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.

    Abdulraheem A · Surgical endoscopy · 2025

    Not a test of Semaglutide alone · 6 results

  9. Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study.

    Brown A · Surgical endoscopy · 2025

    Not a test of Semaglutide alone · 6 results

  10. Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the American College of Physicians.

    Jenniskens K · Annals of internal medicine · 2026

    Not a test of Semaglutide alone · 5 results

  11. Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study.

    Gojani EG · International journal of molecular sciences · 2025

    Not a test of Semaglutide alone · 6 results

  12. Effect of glucagon-like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta-analysis.

    Ali A · Clinical obesity · 2025

    Not a test of Semaglutide alone · 8 results

  13. First report on a case series of Patulous Eustachian tube following GLP-1 receptor agonist-induced weight loss.

    Sudhoff H · European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025

    Not a test of Semaglutide alone · 6 results

  14. Evaluation of Insulin Dosage After the Addition of Tirzepatide Compared With Semaglutide or Dulaglutide in Patients With Type 2 Diabetes.

    McKone DB · Diabetes spectrum : a publication of the American Diabetes Association · 2025

    Not a test of Semaglutide alone · 14 results

  15. GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.

    King AC · Journal of addiction medicine · 2026

    Not a test of Semaglutide alone · 9 results

  16. Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years.

    Thiyagarajan S · Obesity surgery · 2026

    Not a test of Semaglutide alone · 6 results

  17. Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus.

    Park MJ · American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026

    Not a test of Semaglutide alone · 12 results

  18. Case Report: Clinical pharmacist prescriber in depression treatment in primary care settings: clinical case focused on prescribing practice.

    Stuhec M · Frontiers in psychiatry · 2025

    Not a test of Semaglutide alone · 3 results

  19. Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis.

    Cheng PL · Diabetes research and clinical practice · 2026

    Not a test of Semaglutide alone · 3 results

  20. Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies.

    Anatriello A · Frontiers in pharmacology · 2026

    Not a test of Semaglutide alone · 3 results

  21. Déjà vu! A Case of Recurrent Metabolic Dysfunction-Associated Steatohepatitis 70 Days After Liver Transplantation.

    Still M · ACG case reports journal · 2026

    Not a test of Semaglutide alone · 3 results

  22. Prescription Sequence Symmetry Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Neuropsychiatric Conditions.

    Alfonso Arvez MJ · Clinical pharmacology and therapeutics · 2026

    Not a test of Semaglutide alone · 6 results

  23. Semaglutide-Induced Sarcopenia via GLP-1R-mTOR-Satellite Cells Axis and Muscle-Glucose Feedback Loop Potentially Leading to Refractory Hyperglycemia in Type 2 Diabetes: A Case-Driven Hypothesis.

    Ahmed A · Problemy endokrinologii · 2026

    Not a test of Semaglutide alone · 3 results

  24. Carnitine Deficiency Caused by Salcaprozic Acid Sodium Contained in Oral Semaglutide in a Patient with Multiple Acyl-CoA Dehydrogenase Deficiency.

    Mikami-Saito Y · International journal of molecular sciences · 2025

    Not a test of Semaglutide alone · 3 results

  25. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.

    Mantovani A · The lancet. Gastroenterology & hepatology · 2022

    Not a test of Semaglutide alone · 4 results

  26. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis.

    Monami M · Experimental diabetes research · 2012

    Not a test of Semaglutide alone · 4 results

  27. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis.

    Berg S · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025

    Not a test of Semaglutide alone · 5 results

  28. Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists.

    Barrett TS · JAMA surgery · 2025

    Not a test of Semaglutide alone · 9 results

  29. Trends in glucagon-like peptide 1 receptor agonist prescribing patterns.

    Ukhanova M · The American journal of managed care · 2025

    Not a test of Semaglutide alone · 4 results

  30. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.

    Harrison SA · Contemporary clinical trials · 2020

    Not a test of Semaglutide alone · 2 results

  31. Fusion Outcomes of GLP-1 Agonist Therapy in Multilevel Cervical Spinal Fusion: A Propensity-Matched Analysis.

    Vatsia SK · Clinical spine surgery · 2025

    Not a test of Semaglutide alone · 8 results

  32. GLP-1 receptor agonists for treating obesity without diabetes: A systematic review and meta-analysis of economic evaluations.

    Dhippayom T · Diabetes, obesity & metabolism · 2026

    Not a test of Semaglutide alone · 4 results

  33. Cost-effectiveness analysis of once-weekly semaglutide vs. once-daily liraglutide administered subcutaneously in patients with overweight and obesity: a decision analysis.

    Alshahawey M · European review for medical and pharmacological sciences · 2024

    Not a test of Semaglutide alone · 4 results

  34. Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.

    Samuels JM · Diabetes, obesity & metabolism · 2024

    Not a test of Semaglutide alone · 6 results

  35. Bariatric surgery vs. GLP-1 receptor agonists among primarily medicare and medicaid patients with diabetes: a 3-year analysis.

    Brown A · Surgical endoscopy · 2026

    Not a test of Semaglutide alone · 4 results

  36. Proteomic effects of short-term liraglutide vs. placebo in a blinded crossover RCT: Implications for efficacy, safety, and comparison with semaglutide.

    Stefanakis K · Metabolism: clinical and experimental · 2026

    Not a test of Semaglutide alone · 19 results

  37. TikTok's take on adverse effects for glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.

    Wantuch GA · Journal of the American Pharmacists Association : JAPhA · 2025

    Not a test of Semaglutide alone · 4 results

  38. New onset diabetic retinopathy with glucagon-like peptide-1 receptor agonists: A case report.

    Ko J · Journal of the American Pharmacists Association : JAPhA · 2025

    Not a test of Semaglutide alone · 2 results

  39. Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report.

    Gandecka-Pempera A · Frontiers in endocrinology · 2025

    Not a test of Semaglutide alone · 2 results

  40. Real-World Effectiveness of Finerenone Added to SGLT2 Inhibitor and GLP-1 Receptor Agonist Therapy in Individuals with Type 2 Diabetes and Chronic Kidney Disease.

    Nakhleh A · Journal of clinical medicine · 2025

    Not a test of Semaglutide alone · 7 results

  41. Obesity Management Pharmacotherapies and Lifestyle Treatment for Pediatric Obesity Management: A Systematic Review and Network Meta-Analysis.

    Wan KW · JAMA pediatrics · 2026

    Not a test of Semaglutide alone · 2 results

  42. Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.

    Gabery S · Life sciences · 2025

    Not a test of Semaglutide alone · 12 results

  43. Investigating GLP-1 Injections: Potential Mitochondrial Dysfunction in Non-Diabetic Patients Presenting with Migraines and Hypoglycemia: A Case Report.

    Jamail J · Integrative medicine (Encinitas, Calif.) · 2024

    Not a test of Semaglutide alone · 4 results

  44. Weight Loss Effects of Glucagon-Like Peptide-One Receptor Analog Treatment in a Severely Obese Patient During Hospital Admission.

    Figueredo Y · Cureus · 2023

    Not a test of Semaglutide alone · 4 results

  45. Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study.

    Matsunuma S · International journal of clinical pharmacology and therapeutics · 2026

    Not a test of Semaglutide alone · 2 results

  46. Quadruple Non-Insulin Therapy for Advanced Type 2 Diabetes Mellitus With Cognitive Impairment: A Case Report.

    Skudar S · Cureus · 2026

    Not a test of Semaglutide alone · 2 results

  47. Pre-operative concerns and post-operative satisfaction: comparing attitudes toward bariatric surgery and medication intervention for weight loss on Reddit.

    Del Carmen GA · Surgical endoscopy · 2026

    Not a test of Semaglutide alone · 2 results

  48. Hypertensive disorders of pregnancy and GLP-1 receptor agonist timing: a systematic review and meta-analysis.

    Pisani D · Endocrine · 2026

    Not a test of Semaglutide alone · 6 results

  49. Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.

    Tong LH · Journal of chromatography. A · 2026

    Not a test of Semaglutide alone · 13 results

  50. Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.

    Ren L · Diabetes, obesity & metabolism · 2026

    Not a test of Semaglutide alone · 8 results

How PepBank reports evidence